Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study

BMC Clinical Pharmacology

Brian Scheckner¹  Ben Adeyi¹  Bryan Dirks¹  Thomas Babcock¹ 

[1] Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA, 19087, USA

关键词: Switching treatment;    Adult;    ADHD;    Attention-deficit hyperactivity disorder;    Amphetamines;    LDX;    Lisdexamfetamine dimesylate;   

Others  :  860701
DOI  :  10.1186/2050-6511-13-18

 received in 2012-04-17, accepted in 2012-12-10,  发布年份 2012

【 摘 要 】

Background

To examine the efficacy of lisdexamfetamine dimesylate (LDX) in adults with attention-deficit/hyperactivity disorder (ADHD) who remained symptomatic (ADHD Rating Scale IV [ADHD-RS-IV] total score >18) on amphetamine (AMPH) therapy (mixed AMPH salts and/or d-AMPH formulations) prior to enrollment in a 4-week placebo-controlled LDX trial vs the overall study population. In these post hoc analyses from a multicenter, randomized, double-blind, forced-dose titration study, clinical efficacy of LDX (30-70 mg/d) in adults with ADHD receiving AMPH treatment at screening vs the overall study population was evaluated. ADHD symptoms were assessed using the ADHD-RS-IV with adult prompts at screening, baseline (after prior treatment washout), and endpoint. Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, laboratory findings, and electrocardiogram.

Results

Of 414 participants (62, placebo; 352, LDX) included in the overall study population, 41 were receiving AMPH therapy at screening (2, placebo; 39, LDX); mean AMPH dose was 35.0 and 34.1 mg/d for participants in placebo and all LDX groups, respectively. Of the 41 participants, 36 remained symptomatic (ADHD-RS-IV >18) at screening despite receiving AMPH. For the 36 participants in the placebo (n = 2) and LDX (n = 34) groups, respectively, at endpoint, mean change from screening ADHD-RS-IV total scores were -5.5 and -14.8 and from baseline scores were -13.5 and -17.8. For the overall study population, endpoint mean change from baseline ADHD-RS-IV total scores were -7.8 for placebo and -17.5 for LDX. In the prior AMPH subgroup, 2/2 (100.0%) in the placebo group and 22/39 (56.4%) participants in the LDX (all doses) group reported any TEAE. Events that occurred in ≥5% for LDX were dry mouth (5/39; 12.8%), headache (5/39; 12.8%), fatigue (3/39; 7.7%), insomnia (3/39; 7.7%), decreased appetite (2/39; 5.1%), and nausea (2/39; 5.1%). None of these events occurred in the 2 placebo patients with prior AMPH use.

Conclusion

In these post hoc analyses, adults with significant baseline ADHD symptoms despite adequate AMPH treatment dose showed similar improvements in ADHD symptoms with LDX treatment as the overall study population. Prospective studies are needed to confirm these findings. The safety profile of LDX in the overall study population was consistent with long-acting psychostimulant use.

Trial registry

Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). Clinicaltrials.gov Identifier: NCT00334880

【 授权许可】

   
2012 Babcock et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, et al.: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006, 163(4):716.
• [2]Pliszka SR, Crismon ML, Hughes CW, Conners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M, The Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder: The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006, 45(6):642.
• [3]Canadian ADHD Resource Alliance: Canadian ADHD practice guidelines. CAP-guidelines 3rd edition. http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011.pdf webcite. Accessed September 13, 2012
• [4]Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, et al.: Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007, 21(1):10.
• [5]Arnold LE: Methylphenidate vs. amphetamine: comparative review. J Atten Disord 2000, 3(4):200.
• [6]Burke WJ, Bose A, Wang J, Stahl SM: Switching depressed patients from citalopram to escitalopram is well tolerated and effective. In Poster Presented at: American College of Neuropsychopharmacology's 42nd Annual Meeting; December 7-11, 2003. San Juan, Puerto Rico;
• [7]Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, et al.: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006, 354(12):1231.
• [8]Cantwell DP: Attention deficit disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996, 35(8):978.
• [9]Pelham W Jr, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE: Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990, 86(2):226.
• [10]Arnold LE, Lindsay RL, Conners CK, Wigal SB, Levine AJ, Johnson DE, West SA, Sangal RB, Bohan TP, Zeldis JB: A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2004, 14(4):542.
• [11]Vyvanse [package insert]. Wayne, PA: Shire US Inc; 2012.
• [12]Pennick M: Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010, 6(1):317.
• [13]Adderall XR [package insert]. Wayne, PA: Shire US Inc; 2011.
• [14]Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J, on behalf of the 316 Study Group: Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using the adult workplace environment design. Behav Brain Funct 2010, 6:34. BioMed Central Full Text
• [15]Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L, on behalf of the 304 Study Group: Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr 2009, 14(10):573.
• [16]Lasser R, Dirks B, Adeyi B, Babcock T: Comparative efficacy and safety of lisdexamfetamine dimesylate and mixed amphetamine salts extended release in adults with attention-deficit/hyperactivity disorder. Prim Psychiatr 2010, 17(9):44.
• [17]Biederman J, Spencer TJ, Wilens TE, Weisler RH, Read SC, Tulloch SJ, on behalf of the SLI 381.304 Study Group: Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 2005, 10(12 suppl 20):16.
• [18]Weisler RH, Biederman J, Spencer TJ, Wilens TE, Faraone SV, Chrisman AK, Read SC, Tulloch SJ, on behalf of the SLI381.303 Study Group: Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006, 11(8):625.
• [19]Haffey MB, Buckwalter M, Zhang P, Homolka R, Martin P, Lasseter KC, Ermer JC: Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med 2009, 121(5):11.
• [20]Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, Biederman J, on behalf of the 303 Study Group: Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008, 69(9):1364.
• [21]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
• [22]DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998.
• [23]Adler L, Cohen J: Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004, 27(2):187.
• [24]Guy W: Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch; 1976:218-222.
• [25]Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH: A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003, 112(5):e404.
• [26]Steele M, Jensen PS, Quinn DMP: Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 2006, 28(11):1892.
• [27]Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, et al.: Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001, 40(2):168.
• [28]Elia J, Borcherding BG, Rapoport JL, Keysor CS: Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res 1991, 36(2):141.
• [29]Joyce BM, Glaser PE, Gerhardt GA: Adderall produces increased striatal dopamine release and a prolonged time course compared to amphetamine isomers. Psychopharmacology (Berl) 2007, 191(3):669.
• [30]Ermer J, Homolka R, Martin P, Buckwalter M, Purkayastha J, Roesch B: Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol 2010, 50(9):1001.
• [31]Shojaei A, Ermer JC, Krishnan S: Lisdexamfetamine dimesylate as a treatment for ADHD: dosage formulation and pH effects. In Poster Presented at: 160th Annual Meeting of the American Psychiatric Association; May 19-24, 2007. San Diego, CA: Poster NR; 740.
• [32]Krishnan S, Zhang Y: Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol 2008, 48(3):293.
• [33]Rowley H, Heal D, Hackett D: Simultaneous measurement with hysteresis analyses of the effects of lisdexamfetamine dimesylate and d-amphetamine on striatal levels of extracellular dopamine, locomotor activity, and plasma drug concentrations in freely-moving rats. In Poster Presented at: New Clinical Drug Evaluation Unit Annual Meeting; June 13-16, 2011. Boca Raton, FL;
• [34]Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, et al.: Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002, 41(2 suppl):26S.
• [35]Jain R, Babcock T, Burtea T, Dirks B, Adeyi B, Scheckner B, Lasser R: Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. Child Adolesc Psychiatry Ment Health 2011, 5(1):35. BioMed Central Full Text